Two cases of myelofibrosis with severe thrombocytopenia and symptomatology successfully treated with combination of pomalidomide and ruxolitinib

Modest activity of pomalidomide in patients with myelofibrosis and significant anemia

(2013) Naval Daver et al.   LEUKEMIA RESEARCH

Biology and Clinical Management of Myeloproliferative Neoplasms and Development of the JAK Inhibitor Ruxolitinib

(2012) J. Mascarenhas et al.   CURRENT MEDICINAL CHEMISTRY

A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

(2012) Srdan Verstovsek et al.   NEW ENGLAND JOURNAL OF MEDICINE

JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis

(2012) Claire Harrison et al.   NEW ENGLAND JOURNAL OF MEDICINE

Long-term outcome of pomalidomide therapy in myelofibrosis

(2011) Kebede H. Begna et al.   AMERICAN JOURNAL OF HEMATOLOGY

Circulating Interleukin (IL)-8, IL-2R, IL-12, and IL-15 Levels Are Independently Prognostic in Primary Myelofibrosis: A Comprehensive Cytokine Profiling Study

(2011) Ayalew Tefferi et al.   JOURNAL OF CLINICAL ONCOLOGY

Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation

(2009) N. Kroger et al.   BLOOD

Pomalidomide Is Active in the Treatment of Anemia Associated With Myelofibrosis

(2009) Ayalew Tefferi et al.   JOURNAL OF CLINICAL ONCOLOGY

The Myelofibrosis Symptom Assessment Form (MFSAF): An evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis

(2009) Ruben A. Mesa et al.   LEUKEMIA RESEARCH

Low-dose thalidomide in myelofibrosis

(2008) R. Weinkove et al.   HAEMATOLOGICA